- Home
- BPTH
as 07-26-2024 4:00pm EST
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | BELLAIRE |
| Market Cap: | 3.4M | IPO Year: | N/A |
| Target Price: | $30.00 | AVG Volume (30 days): | 101.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -26.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.59 - $22.40 | Next Earning Date: | 08-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Bio-Path Holdings Inc. News
BPTH Breaking Stock News: Dive into BPTH Ticker-Specific Updates for Smart Investing
GlobeNewswire
19 days ago
Bio-Path Holdings Provides Clinical Update and Expansion Plans
GlobeNewswire
a month ago
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
GlobeNewswire
2 months ago
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Newsfile
2 months ago
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
GlobeNewswire
2 months ago
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
GlobeNewswire
2 months ago
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
2 months ago
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
GlobeNewswire
2 months ago
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
Compare BPTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BPTH Bio-Path Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.